Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 209,928
  • Shares Outstanding, K 107,106
  • Annual Sales, $ 322,070 K
  • Annual Income, $ 130,130 K
  • 60-Month Beta 1.11
  • Price/Sales 0.63
  • Price/Cash Flow 1.08
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.16
  • Number of Estimates 2
  • High Estimate 0.78
  • Low Estimate -0.45
  • Prior Year 1.95
  • Growth Rate Est. (year over year) -91.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7000 +13.53%
on 07/29/20
2.8900 -33.22%
on 07/21/20
-0.0100 (-0.52%)
since 07/02/20
3-Month
1.7000 +13.53%
on 07/29/20
2.8900 -33.22%
on 07/21/20
+0.0300 (+1.58%)
since 05/05/20
52-Week
1.2200 +58.20%
on 09/05/19
5.3300 -63.79%
on 12/10/19
+0.6000 (+45.11%)
since 08/05/19

Most Recent Stories

More News
GTCR and TerSera Therapeutics Announce Acquisition of Xermelo

, /PRNewswire/ -- GTCR, a leading private equity firm, announced today that its TerSera Therapeutics LLC ("TerSera") portfolio company has entered into a definitive agreement to acquire the product Xermelo®...

LXRX : 1.9100 (-2.55%)
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of -12.28% and 5.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

LXRX : 1.9100 (-2.55%)
Thinking about buying stock in Edesa Biotech, iBio Inc, Pfizer Inc, Lexicon Pharmaceuticals, or Apache Corp?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EDSA, IBIO, PFE, LXRX, and APA.

APA : 16.43 (+3.46%)
IBIO : 4.43 (+0.91%)
LXRX : 1.9100 (-2.55%)
PFE : 38.25 (-0.36%)
Lexicon: 2Q Earnings Snapshot

THE WOODLANDS, Texas (AP) _ Lexicon Pharmaceuticals Inc. (LXRX) on Thursday reported a loss of $69.1 million in its second quarter.

LXRX : 1.9100 (-2.55%)
Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain

LXRX : 1.9100 (-2.55%)
Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon's rights, title...

LXRX : 1.9100 (-2.55%)
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2020.

LXRX : 1.9100 (-2.55%)
Lexicon Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call and Webcast on July 30, 2020

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2020 financial results on Thursday, July 30, 2020 before market opens. Management will conduct a conference call and live webcast...

LXRX : 1.9100 (-2.55%)
Thinking about buying stock in New Age Beverages, Lexicon Pharmaceuticals, Miragen Therapeutics, Opko Health, or Niu Technologies?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBEV, LXRX, MGEN, OPK, and NIU.

LXRX : 1.9100 (-2.55%)
MGEN : 1.1700 (+2.63%)
NBEV : 2.31 (+2.67%)
OPK : 5.40 (+0.75%)
Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS. The final results of these...

LXRX : 1.9100 (-2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade LXRX with:

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

2nd Resistance Point 2.0667
1st Resistance Point 2.0133
Last Price 1.9100
1st Support Level 1.8833
2nd Support Level 1.8067

See More

52-Week High 5.3300
Fibonacci 61.8% 3.7600
Fibonacci 50% 3.2750
Fibonacci 38.2% 2.7900
Last Price 1.9100
52-Week Low 1.2200

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar